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ABSTRACT
Marek’s disease (MD) is a neoplastic disease of poultry caused by Marek’s disease 
virus (MDV), a highly contagious alphaherpesvirus. Meq, the major MDV oncoprotein, 
induces neoplastic transformation of T-cells through several mechanisms, including 
inhibition of apoptosis. In contrast, the chicken anemia virus (CAV)-encoded protein 
apoptin (VP3) is a powerful inducer of apoptosis of tumor cells, a property that is 
exploited for anticancer therapeutics. Although the molecular mechanisms of selective 
induction of tumor cell apoptosis by apoptin are not fully understood, its tumor cell–
restricted nuclear translocation is thought to be important. Co-infection with MDV 
and CAV is common in many countries, CAV antigens are readily detectable in MD 
lymphomas, and the MDV-transformed T-lymphoblastoid cell lines such as MSB-1 is 
widely used for propagating CAV for vaccine production. As MDV-transformed cell 
lines express high levels of Meq, we examined here whether CAV-encoded apoptin 
interacts with Meq in these cells. Using immunofluorescence microscopy, we found 
that apoptin and Meq co-localize to the nucleus, and biochemical analysis indicated 
that the two proteins do physically interact. Using a combination of Meq mutagenesis 
and co-immunoprecipitation, we demonstrate that apoptin interacts with Meq 
within a region between amino acids 130 and 140. Results from the IncuCyte assay 
suggested that Meq inhibits apoptin-induced apoptosis activity. In summary, our 
findings indicate that Meq interacts with and inhibits apoptin. Insights into this novel 
interaction between Meq and apoptin will relevance for pathogenesis of coinfections 
of the two viruses and in CAV vaccine production using MDV-transformed cell lines. 
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INTRODUCTION
As a rapid-onset neoplastic disease of chickens, 
Marek’s disease (MD), caused by the highly contagious 
Marek’s disease virus (MDV), is generally considered 
an excellent model for studying virus-induced 
T-cell lymphomas. A number of MDV-transformed 
T-lymphoblastoid cell lines derived from primary 
lymphomas have been established by different laboratories. 
MSB-1 is one of the first such cell lines established [1, 2], 
and has since been studied extensively to understand the 
molecular basis of MDV latency [3]. MDV establishes a 
latent infection in most of the cells in these cell lines, and 
the viral gene expression in MSB-1 is restricted to a very 
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limited set of genes, which include the major oncoprotein 
Meq encoded from the transcriptionally active repeat 
regions of the MDV genome [4]. Meq, a basic leucine 
zipper (b-ZIP) transcription factor critical for MDV 
oncogenicity, is primarily expressed in the nucleus [5] 
although it can be detected in the cytoplasm during certain 
stages of the cell cycle [6]. Transcriptional function of Meq 
is dependent on its dimerization with bZIP proteins such 
as c-Jun, c-Fos and ATF-3 [7, 8]. Meq also has non-bZIP 
interactions with transcriptional co-repressor CtBP [9] 
and tumour suppressor protein p53 [10], and can inhibit 
apoptosis through the regulation of Bcl2 and p53 [10–12].
Chicken anemia virus (CAV) is a major avian 
pathogen associated with severe economic losses 
throughout the world [13]. First identified during an 
outbreak of MD, CAV infection leads to the development 
of anemia, immunosuppression and increased mortality 
[14]. VP1, VP2 and VP3 are three proteins encoded 
by CAV. The 121 amino acid-long VP3 (also known as 
apoptin) has been extensively studied due to its unique 
property of inducing cell cycle arrest and apoptosis 
exclusively in transformed cells [15, 16]. The ability of 
apoptin to induce apoptosis selectively in transformed 
cells, but not in normal cells, is thought to be related 
to its accumulation in the nucleus, since apoptin has 
a cytoplasmic location in untransformed cells. This is 
dependent on nuclear localization (NLS) and nuclear 
export (NES) signals present respectively at the N and C 
terminal of apoptin [17, 18]. The nuclear accumulation 
of apoptin is also be influenced by oncoproteins such as 
the SV40 large T-antigen [19] and Bcr-Abl [20]. It has 
also been shown that DNA damage response induces 
nuclear re-localization of apoptin in primary cells [21]. 
Apoptin has been shown to interact with multiple partners 
including HIPPI, HSP70, APC1 and Bcr-Abl, the p85 
subunit of PI3-Kinase and AKT and DEDAF [20, 22–27]. 
The best-characterised binding motif for apoptin is the 
SH3 domain that is present in Bcr-Abl and p85 subunit 
of PI3-Kinase [20], outside of this domain an apoptin 
interacting motif has not been described. The induction of 
apoptosis by apoptin occurs in a p53-independent manner 
[28] and is not always affected by the anti-apoptotic Bcl-2 
protein [29, 30]. It is long known that MDV-transformed 
T-cell lines such as MSB-1 can support the replication 
of CAV [31]. Similarly, experimental studies showed 
infection of MD lymphomas by CAV [32]. Since both 
MSB-1 and MD lymphomas express high levels of Meq, 
we examined whether there is any physical and functional 
interaction between apoptin and Meq.
RESULTS
Localization of Meq and apoptin
The potential physical interaction between the two 
proteins was investigated initially by immunofluorescence 
analysis in chicken embryo fibroblasts (CEF) transfected 
with Meq and an N-terminal FLAG-tagged apoptin (FLAG-
Apoptin) expression constructs. Using specific polyclonal 
rabbit anti-Meq and monoclonal anti-FLAG antibodies 
respectively, we demonstrated nuclear co-localisation of 
Meq and apoptin in the transfected cells (Figure 1). While 
Meq expression was restricted almost exclusively to the 
nucleus, apoptin was distributed both in the nucleus and the 
cytoplasm of CEF (Figure 1A). Nuclear co-localisation of the 
two viral proteins was also demonstrated in transfected DF-1 
cells, an immortalized chicken embryo fibroblast-derived 
cell line (Figure 1B). We also used immunofluorescence 
assay to examine whether apoptin co-localised with the 
endogenously expressed Meq in MSB-1 cells. MSB1 cells 
are known for endogenous expression of Meq protein [4]. 
Transfection of FLAG-tagged apoptin construct into MSB-1 
showed co-localisation of endogenous Meq with transfected 
FLAG-tagged apoptin in the nucleus (Figure 1C).
Interaction of Meq and apoptin 
GST-pull down assays were performed to obtain 
biochemical evidence for physical interaction between 
Meq and apoptin. N-terminal GST-apoptin fusion protein 
expressed in E. coli purified using glutathione sepharose 
beads and MSB-1 cell lysates that express the full length 
Meq protein were used in the assay. Detection of Meq in 
the western blots using the anti-Meq monoclonal antibody 
FD7 (Figure 2A) showed that GST-apoptin can pull down 
Meq from the MSB-1 lysate, demonstrating the interaction 
between the two proteins. For further confirmation of the 
interaction, we also carried out the reverse experiment 
asking whether N-terminal GST-Meq (1–170 aa) fusion 
protein can pull down apoptin from the cell lysates of 
U2OS cell line that expressed N-terminal FLAG-tagged 
apoptin from a doxycycline-inducible construct. Western 
blot analysis with monoclonal antibodies against Meq and 
FLAG also confirmed the interactions between apoptin and 
the N-terminal (1–170 aa) domain of Meq (Figure 2B). 
For the further confirmation of the interaction 
of the two proteins, immunoprecipitation assays were 
performed using the same expression constructs used in 
the immunofluorescence assay. Briefly, DF-1 cells were 
transfected with the Meq and FLAG-apoptin expression 
constructs. After 24–48 hours, transfected cells were 
lysed, pre-cleared and complexes precipitated using the 
appropriate antibody and protein-G sepharose beads 
before western blot analysis using specific antibodies. 
Specific reciprocal immunoprecipitation of apoptin-Meq 
complexes using Meq (Figure 2C) and FLAG (Figure 2D) 
antibodies provided further evidence for biochemical 
interactions of the two proteins.
Apoptin interaction occurs between 130 and 140 
amino acid residues of Meq
Immunoprecipitation assays were also used to 
identify the apoptin-interacting domain within Meq 
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Figure 1: Localisation of Meq and Apoptin. Immunofluorescence was carried out on (A) CEF and (B) DF-1 cells transfected with 
expression constructs containing wild type Meq and N-terminally FLAG tagged Apoptin. Cells were fixed after 24–48 hours and stained 
with polyclonal Meq (green fluorescence) or monoclonal FLAG (red fluorescence) antibodies. In both cases CEF and DF-1 cells showed 
localisation of both Apoptin and Meq in the nucleus of the transfected cells. (C) MSB-1 cells were transfected with FLAG-Apoptin, fixed 
and then stained for endogenous levels of Meq (red fluorescence) or FLAG tagged Apoptin (green fluorescence). In MSB-1 cells Apoptin 
was also localised in the nucleus along with Meq. Upper panel figures of (A), (B) and (C) were from CEF, DF-1 and MSB-1 isotype 
controls/cells, respectively. Confocal photomicrographs are representative of three independent experiments on CEF, DF-1 and MSB-1 
cells. Scale bar represents 40 μm.
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protein. For this, we initially used Meq constructs used 
to demonstrate the interactions of Meq with CtBP and 
BZIP-domain containing proteins [9, 33]. Expression 
constructs of Meq-CtBP with a mutation in the CtBP-
binding motif or Meq-BZIP with a non-functional leucine 
zipper motif [9, 33] were co-transfected into DF-1 cells 
along with FLAG-apoptin construct and complexes 
precipitated using polyclonal rabbit anti-Meq antibodies. 
Detection of precipitated complexes in Western blotting 
assay with monoclonal FLAG antibody demonstrated 
that both these mutations did not affect the interaction of 
apoptin with Meq (Figure 3A). In order to identify the 
putative apoptin-interacting domains within Meq, we 
then generated N-terminal HA tagged full length Meq 
(1–339) and a series of C-terminal truncated Meq constructs 
(1–80, 1–130, 1–140 and 1–170 amino acid residues) 
in pcDNA3.1 vector (Figure 3B). Each of these Meq-
expression constructs were co-transfected with FLAG-
apoptin plasmid into DF-1 cells and protein complexes 
immunoprecipitated with anti-Meq or anti-FLAG 
antibodies. SDS-PAGE-resolved immunoprecipitates and 
were subjected to Western blot analysis with HA-tagged 
antibody. The ability of the N-terminal 140, 170 and the 
full length Meq constructs, but not the N-terminal 80 or 
the 130 constructs, to pull down apoptin indicated that the 
potential interaction of apoptin occurs between amino acids 
130 and 140 of Meq (Figure 3C).
Meq inhibits apoptin in DF-1 cells
We next wanted to investigate the functional 
significance of Meq-apoptin interactions. With apoptin 
functioning as a strong inducer of apoptosis, and Meq 
known for its apoptosis-inhibitory function [10–12], we 
examined the effects of their interactions on apoptosis in 
the presence of Caspase 3/7 Apoptosis Assay Reagent. 
IncuCyte ZOOM Live-Cell Imaging system was used for 
kinetic monitoring of apoptosis on DF-1 cells transfected 
with the two proteins individually or together. Fluorescent 
images collected at every 2 hour intervals. Quantitation of 
apoptosis from the fluorescent images collected at every 
2 hour intervals showed that apoptosis was significantly 
Figure 2: Meq and Apoptin interact. Initially GST-pull-down assays were used to investigate if Meq and Apoptin interact. The 
pulldown assays were performed both ways. (A) GST-Apoptin was used against MSB-1 lysate and (B) GST-Meq (1–170) against induced 
U2OS-Apoptin lysate. Lysates were incubated with GST and GST-Meq (1–170) or GST-Apoptin. Bound protein were resolved on an SDS 
4–12% Bis-Tris gel along with 10% of input protein and western blotted with Meq and monoclonal FLAG antibodies respectively. The 
GST pull-down showed that Meq interacts with GST-Apoptin and Apoptin interacts with GST-Meq (1–170). Immunoprecipitation was 
then carried out using DF-1 cells co-transfected with Meq and N-terminal tagged FLAG-Apoptin. Protein complexes were pulled out using 
(C) rabbit anti-Meq and (D) anti FLAG. Bound protein were resolved on an SDS 4–12% Bis-Tris gel along with 10% of input protein and 
western blotted with FLAG and monoclonal Meq antibodies respectively. Both Meq and Apoptin were able to pull out the other protein 
from the lysate demonstrating that strong interaction occur between them. GST was negative control in (A) and (B) in pull down assays. 
Rabbit anti-mouse was isotype control in (C) and (D) in immunoprecipitation assays. Western blot figures are representative of three 
independent experiments of GST-pull-down and immunoprecipitation assays of Meq and Apoptin.
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lower between 60 and 92 h in the Meq-apoptin co-
transfected cells than in the cells transfected only with 
apoptin (Figure 4A). As shown in Figure 4A, the levels 
of apoptosis was also significantly lower in the Meq-
transfected cells compared to the apoptin-transfected cells 
between 68 and 92 h, except at 74 h (M ± SE, n = 6).
The kinetics of apoptotic cells at 0, 60, and 90 h 
are illustrated in Figure 4B. Supplementary videos 1 to 6 
represent the apoptotic cells kinetics between 0 and 92 h 
of Apoptin, Meq, Meq-Apoptin, Transfection control, 
Caspase 3/7 control and negative control cells, respectively.
The phase confluence of cells was inversely related to 
apoptosis (green object count) of cells, and Meq-transfected 
cells (either alone or when co-transfected with apoptin) 
showed significantly higher phase confluence than apoptin 
transfected cells after 50 h (data not shown). This data 
demonstrating the inhibitory effect of Meq on the apoptosis-
inducing function was also confirmed independently using 
xCELLigence [34] system (data not shown).
Further, to understand the significance of the 
130–140 amino acid region of Meq, a synthetic peptide 
(Cambridge peptides, Birmingham, UK) mimicking the 
region (YPYDVPDYA-LTVTLGLLTTP; HA-tagged to 
N-terminal of 130–140 amino acids of Meq) was evaluated 
for its ability to inhibit Meq-apoptin interactions in DF-1 
cells. Meq synthetic peptide 130–140 was transfected 
into DF-1 cells by using the Chariot Transfection system, 
according to the manufacturer instructions (Active motif, 
Rixensart, Belgium). β-galactosidase was used as positive 
control for the Chariot Transfection reagent (Active motif, 
Rixensart, Belgium). To analyze the functional effects of the 
synthetic peptide 130–140, the number of Meq and apoptin 
co-localized cells were evaluated in the presence or absence 
of synthetic peptide by using a confocal microscope. Ten 
Figure 3: Meq and Apoptin do not interact through Meq-CtBP or Meq-BZIP motifs, but interact between 130 and 
140 amino acids of Meq. (A) Immunoprecipitation was carried out using DF-1 cells co-transfected with Meq, Meq-CtBP or Meq-
BZIP mutants and N-terminally tagged FLAG-Apoptin. Protein complexes were pulled out using (Figure 2C) rabbit anti-Meq and (Figure 
2D) anti FLAG. Bound protein were resolved on an SDS Bis-Tris gel along with 10% of input protein and western blotted with FLAG 
antibodies. Meq was able to pull out Apoptin from the lysate in all cases showing the CtBP motif and leucine zipper were not crucial for 
the interaction. (B) Four C-terminally truncated Meq proteins of the first 80, 130, 140 and 170 amino acids with an N-terminal HA tag were 
constructed to localise the Apoptin interaction domain within Meq. (C) The four truncations of Meq along with the wild type were used in 
immunoprecipitation assays using DF-1 cells co-transfected with N-terminally tagged FLAG-Apoptin. Protein complexes were pulled out 
using mouse anti-Meq and anti-FLAG. Bound protein were resolved on an SDS Bis-Tris gel along with 10% of input protein and western 
blotted with HA-HRP direct conjugate antibodies. Meq was able to pull out Apoptin from the lysate as long as the N-terminal 140 aa were 
present, the N-terminal 80 or 130 amino acids were not sufficient. Suggest the interaction occurs between amino acids 130 and 140. Rabbit 
anti-mouse was isotype control in (A) and mouse anti-Myc was isotype control in (C). Western blot images are representative of triplicate 
experiments.
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randomly selected regions were counted in each condition 
for three independent experiments. We observed that there 
was no change in number of apoptin and Meq co-localized 
cells in presence (1.70 ± 1.25%) or absence (2 ± 1.25%) of 
Meq synthetic peptide 130–140 (M ± SD, n = 3).
DISCUSSION
MD is a good model for studying virus-induced 
T-cell lymphomas. Meq, the major oncoprotein of MDV, 
induces neoplastic transformation of T cells through 
several mechanisms, including inhibition of apoptosis 
[10–12, 35]. As a transcriptional regulator, Meq has a 
nuclear distribution and can function as a Meq/Meq 
homodimer or a heterodimer with a number of other 
cellular BZIP proteins. In the past, we reported that 
Meq interacts with CtBP via the proline-leucine-aspartic 
acid-leucine-serine (PLDLS) motif, an interaction 
critical for induction of lymphomas [9]. Similarly, Meq 
homodimerization was shown to be essential for the 
induction of T-cell lymphoma by MDV [33].
CAV is an economically important virus of chickens, 
causes severe anemia, immunosuppression, lymphoid 
atrophy and mortality [14, 32]. CAV replicates in MDV-
transformed T-cells and MDV-CAV coinfection results in 
increased pathogenesis, despite the molecular interactions 
are remain poorly understood [14, 32, 36]. Although a 
number of interacting partners of Meq or apoptin have 
been identified, [9, 33, 37–40], it is still unclear whether 
Meq and apoptin proteins do directly interact. Here, 
Figure 4: Meq, Apoptin, Meq-Apoptin plasmid transfected DF-1 cells were monitored in real time by the live cells 
imaging system IncuCyte. (A) Meq-Apoptin co-transfected cells apoptosis was significantly lower than Apoptin transfected cells 
between 60 and 92 h. And Meq-transfected cells apoptosis was significantly lower compared to Apoptin-transfected cells between 68 and 
92 h, except at 74 h. Growth curves are shown as means of six independent experiments ± standard error (SE). An asterisk (*) indicates 
statistically significant difference (P < 0.05) between Apoptin and Meq-Apoptin or Meq transfected cells. (B) Representative IncuCyte 
live cells images illustrating evolution of apoptotic cells (green) at 0, 60 and 90 h. Transfection control, Caspase 3/7 positive control and 
negative control cells were used as controls.
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we report for the first time that Meq protein can physically 
interact with apoptin protein, with potential functional 
significance.
Data of immunofluorescence staining, GST pull-
down, and immunoprecipitation assays demonstrated that 
Meq physically interacts with apoptin, and interaction 
was shown to be in a region between amino acids 130 
and 140 of Meq. The CtBP and BZIP-domains are 
not involved in interaction with apoptin. IncuCyte 
ZOOM Live-Cell Imaging and xCELLigence (data 
not shown) assays were used to examine the functional 
significance of Meq-apoptin interaction in DF-1 cells. 
Observations on the inhibition of apoptosis function by 
Meq have corroborated the functional significance of 
the interactions of these proteins, with potential roles in 
MDV and CAV pathogenesis in co-infected chickens. The 
inhibition of apoptin activity by Meq could be crucial 
in T-lymphoblastoid transformation of MDV, and may 
be further helpful for sustenance and dissemination of 
CAV [32, 36]. There have been several reports of viruses 
modulating the cell microenvironment for their own 
advantages [10, 17, 23, 41–47]. Indeed, both Meq and 
apoptin modulate the cell cycle machineries [17, 23, 47] 
and maintenance of favorable cellular conditions for viral 
replication is strategically important during co-infections 
with the two viruses [45, 46, 48]. Further studies on CD4+ 
and CD8+ T cells populations of lymphomas collected 
from co-infected chickens will help to understand the 
role and significance of these complex interactions in 
co-pathogenesis of CAV and MDV [32, 36]. Further 
insights into the Meq-apoptin interactions are also 
valuable to examine the interactions of apoptin with other 
oncoproteins such as EBNA3A/C of Epstein-Barr virus 
or EVI1 of myeloid leukaemia [49, 50], because of their 
interactions with CtBP [9, 50].
As mentioned earlier, apoptotic function of apoptin 
in transformed cells is reliant on its translocation to 
the nucleus [17, 18]. Although we have observed co-
localisation of Meq and apoptin in the nucleus of 
transfected fibroblasts and in MSB-1 cells (Figure 1), 
we don’t know whether Meq and its nuclear localisation 
signals are directly involved in the active nuclear 
translocation of apoptin. Nevertheless, based on the 
interaction of the two proteins, one could suggest the 
possibility that Meq may activate apoptin at threonine 
108 [51] through a Meq-regulated cellular kinase in 
transformed cells as was suggested in the case of SV40 
large-T antigen [19]. In support of this hypothesis, altered 
expression of several kinases has been demonstrated in 
cells overexpressing Meq [12].
Apoptin is known to bind multiple partners including 
Hippi [22, 23], APC1 [23], HSP70 [24], Crm1 protein for 
nuclear export [17], Bcr-Abl oncoprotein [20], p85 subunit 
of PI3-Kinase [25, 26], DEDAF (human death effector 
domain-associated factor) [27], FADD, Bcl 10 [52], and 
PKC (protein kinase C) beta [39]. Recent studies have 
shown that apoptin inhibits Bcr-Abl1 kinases in chronic 
myeloid leukemia (CML), and regulates the activity of 
protein kinase C (PKC) in myeloma cell lines, respectively 
[39, 40]. However, none of these proteins have demonstrated 
a conserved interaction motif, although the larger SH3 
domain of Bcr-Abl1 and PI3-Kinase appear to be involved 
[20, 25, 26]. Our studies using truncated Meq constructs 
have demonstrated the importance of sequences between 
130 and 140 (LTVTLGLLTTP) of Meq in interacting with 
apoptin (Figure 3B and 3C). Although we examined the 
significance of this interacting region (130–140 aa) of Meq 
with a synthetic peptide, we could not demonstrate changes 
in the co-localization of the two proteins in the presence of 
the peptide in DF-1 cells. It might be that the N-terminal 
nuclear localization signal that transports Meq into nucleus 
may also be important for the interaction [5, 17] and the 
absence of the nuclear localization signal might explain 
the lack of the biological activity of this peptide [53]. 
Alternatively, aggregation of the protein in these cells may 
inhibit its effectiveness [53, 54].
Homo/hetero dimerization of Meq and 
multimerization of apoptin are important characteristics that 
are associated with the biological functions of these proteins 
[17, 33, 55], possibly by providing additional interface (s) 
for binding proteins. Previous studies have shown that 
N and C-terminal regions of apoptin have important cell 
killing (apoptotic) activity [18] and it is likely that Meq 
might be interacting with these N and C-terminal regions 
of apoptin to inhibit the apoptotic activity.
Other authors have reported that the biological 
functions of Meq and apoptin are modulated by their 
interactions with multiple protein partners [9, 22–26, 33, 
35, 56]. During MDV-CAV co-infection also, there should 
be multiple molecular partners that would potentially 
interact with the Meq-apoptin complexes. Next step will 
be to identify the Meq interaction domains of apoptin that 
contribute to the inhibition of apoptosis. We will also aim 
to resolve the Meq-apoptin interactome to know their roles 
in MDV-CAV co-pathogenesis.
In summary, we have shown that Meq interacts 
with apoptin, and inhibits apoptin activity. Further 
studies in lymphoblastoid cell lines or chickens are 
needed to get functional insights into MDV and CAV co-
pathogenesis for T-cell transformation and persistence and 
dissemination of CAV.
MATERIALS AND METHODS
Cells
Primary chicken embryo fibroblasts (CEF) 
were collected from 10-day-old embryonated specific 
pathogen free (SPF) eggs [57]. CEFs were used for 
immunofluorescence assay. DF1 cells are continuous 
cell lines of EV-0 chicken embryo fibroblasts [58]. 
DF-1 cells were used for immunofluorescence and 
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immunoprecipitation assays. MSB-1 lymphoblastoid cells 
are T-lymphocyte cell line, and are grown in suspension 
[1, 2]. MSB-1 cells were used for immunofluorescence 
and GST pull-down assays. A human osteosarcoma cell 
line (U2OS) was used for GST pull-down assay. 
Plasmids
Plasmid pcDNA3.1-Meq full length (339 aa), 
MeqCtBP and MeqBZIP expression constructs were used 
and described previously [9, 33]. Plasmid pcDNA3.1 
Flag tagged full length apoptin (FLAG-Apoptin) and 
pRTS apoptin constructs were generated by PCR. The 
C-terminal truncated Meq constructs (1–80, 1–130, 1–140 
and 1–170 aa residues) were generated in order to identify 
the putative apoptin interacting domains within Meq.
Plasmids transfection
CEFs (1 × 106) and DF-1 cells (1 × 106) were plated 
in a six-well culture plates. Meq and N-terminal FLAG 
tagged apoptin expression constructs were transfected into 
CEFs by Lipofectamine and DF-1 cells by Lipofectamine 
2000 reagents respectively (Invitrogen, Karlsruhe, 
Germany). CEFs were 70–80% confluence and DF-1 cells 
were 90–95% at the time of transfection. MSB-1 cells 
(1 × 106) were transfected with plasmid Flag tagged 
apoptin by electroporation (Amaxa Biosystems, 
Nucleofector, Koln, Germany), and was used for 
immunofluorescence staining and GST-pull down assay. 
An inducible human osteosarcoma (U2OS)-apoptin 
cell line was generated by plasmid pRTS apoptin 
transfection into U2OS cells, and subsequently selected 
with puromycin (1 µg/mL). Apoptin protein expression in 
U2OS cells was induced by doxycycline (1 µg/mL), and 
U2OS-apoptin lysate was used for GST-pull down assay. 
The experiments were performed in triplicate.
Immunofluorescence
CEF, DF-1 cells and MSB-1 cells were fixed in 4% 
paraformaldehyde (30 min, Room temperature (RT)) and 
permeabilized with 0.1% Triton X-100 (15 min, RT). Then, 
cells were blocked in 5% bovine serum albumin (BSA) 
in phosphate-buffered saline (PBS) for 30 min. Cells 
were first stained for Apoptin (anti-Flag, clone M2) and 
next for Meq proteins. Cells were incubated (1 h, 37° C) 
with mouse monoclonal anti-Flag antibodies (1:4000 in 
5% BSA), after which cells were washed three times. 
Then, cells were incubated (1 h, 37° C) simultaneously 
with Alexa 568 (CEF and DF-1 cells)/488 (MSB-1 
cells)-conjugated goat anti-mouse (1:200 in 5% BSA) 
and rabbit polyclonal anti-Meq antibodies (1:5000 in 5% 
BSA). Subsequently, after washing, cells were incubated 
with Alexa 488 (CEF and DF-1 cells)/ 568 (MSB-1 
cells)-conjugated goat anti-rabbit antibodies. Finally, 
after washing, cells were stained (10 min, RT) with 
DAPI (1:10000) and viewed by using a Leica (Wetzlar, 
Germany) TCS SP2 confocal laser-scanning microscope.
GST pull-down, immunoprecipitation and 
Western blotting
These assays were performed in three independent 
experiments, essentially as described previously [50]. 
The antibodies used were rabbit anti-Meq (raised against 
GST-Meq-wild type [9], at the Institute for Animal Health, 
Compton, United Kingdom), rabbit-anti-Mouse (Dako, 
Glostrup, Denmark), mouse-anti-Myc (Santa Cruz, 
California, USA), rabbit-anti-FLAG (BD Biosciences 
PharMingen, San Diego, California, USA) and mouse-
anti-Flag (Sigma Aldrich, Saint Louis, Missouri, USA).
IncuCyte apoptosis assay
The functional interactions between Meq and 
apoptin proteins were determined using caspase 3/7 
apoptosis assay, and experiment monitored by IncuCyte 
ZOOM live cell imaging (Essen Bioscience, Michigan, 
USA). Briefly, Meq, apoptin and Meq-apoptin plasmids 
transfected DF-1 cells were seeded at 5000 cells per well 
in a 96 well plate (Corning). After overnight incubation, 
caspase 3/7 reagent (1:1000) was added on cells (Essen 
Bioscience). Images were captured every 2 h for 92 h 
from four separate regions per well using a 10× objective. 
Green object count per well was quantified at each time 
point of Meq, apoptin, Meq-apoptin, transfection control, 
caspase 3/7 positive control and negative control cells. 
IncuCyte data was analysed by one-way analysis of 
variance (ANOVA) with Tukey post hoc comparisons 
using GraphPad Prism version 7.01 (GraphPad Software, 
Inc., San Diego, CA). The results were shown as mean 
± standard error (SE) for six independent experiments. 
P values of < 0.05 were considered to be significant.
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